logo
  

Embecta Sinks As Outlook Comes In Below Consensus

Shares of diabetes care company Embecta Corp. (EMBC) are falling more than 12 percent Friday morning after the company provided full-year profit outlook below the Street view.

Embecta now expects adjusted profit in the range of $1.95 - $2.15 for the full year. Analysts on average, polled by Thomson-Reuters expects the company to report earnings of $2.22 per share.

Revenue for the full year is expected in the range of $1.094 billion - $1.116 billion. This compares with the consensus estimate of $1.1 billion for the year.

EMBC is at $15.48 currently. It has traded in the range of $12.72 - $33.88 in the last 1 year.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
RELATED NEWS
Follow RTT